http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
-
Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
-
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
-
Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation
-
Amgen (AMGN) Completes Acquisition Of Otezla, Updates Guidance
-
Amgen Completes Acquisition Of Otezla® (apremilast)
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Celgene (CELG)
-
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
-
Exelon Corporation (EXC) to Replace Celgene (CELG) in NASDAQ-100 Index
-
Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
-
Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
-
Bristol-Myers (BMY) Receives FTC Clearance for Celgene (CELG) Acquisition, Deal Expected to Close Next Week
-
Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
-
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
-
FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
-
Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting
-
Amgen (AMGN) to Acquire Otezla from Celgene (CELG) for $13.4B
-
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
-
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
-
Bristol-Myers Squibb (BMY) Announces European Commission Approval of Pending Acquisition of Celgene (CELG)
-
Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
-
Bristol-Myers Squibb (BMY) is Planning Divestiture of OTEZLA to Get FTC Clearance for Celgene (CELG) Deal
-
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
-
Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
-
Bristol-Myers Squibb (BMY) Announces Leadership Team Upon Completion of Pending Merger with Celgene (CELG)
-
Bristol-Myers Squibb Announces Post-Closing Leadership Team
-
Celgene (CELG) Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO
-
Celgene Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019
-
Celgene (CELG), Acceleron Pharma (XLRN) Announce FDA Accepts Luspatercept BLA in Myelodysplastic Syndromes and Beta-Thalassemia
-
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
-
Celgene (CELG) Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib
-
Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib
-
Celgene (CELG) Announces Data from a Phase 1/2 Clinical Study of Iberdomide (CC-220) in Combination with Dexamethasone at ASCO 2019 Meetings
-
Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019
-
Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
-
Lyfebulb and Celgene Announce Finalists for 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
-
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
-
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
-
Celgene (CELG), Acceleron Pharma (XLRN) Announce Submission of Luspatercept BLA to U.S. FDA
-
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
-
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
-
Bristol-Myers Squibb (BMY) Confirms ISS and Glass Lewis Recommend Shareholders Vote for Proposed Merger with Celgene (CELG)
-
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
-
Bristol-Myers Squibb (BMY) Board Provides Open Letter Shareholder Regarding Merger Agreement with Celgene Corp. (CELG)
-
Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Mate
-
Bristol-Myers Squibb (BMY) Highlights Significant Benefits of Pending Transaction with Celgene (CELG)
-
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
-
Celgene (CELG) Provides Update on ABRAXANE Combination Therapy in Treatment of Metastatic TNBC and Pancreatic Cancer
-
Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer